Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Novartis125 enrolled

Overview

Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

125

Conditions

Hypertension Left Ventricular Hypertrophy

Interventions

amlodipine/benazeprilDRUG

Eligibility

Sex: ALLMin age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males or female patients ≥ 55 years of age * LVH as confirmed by echocardiogram * Patients with high risk hypertension, currently treated or already taking antihypertensive medication Exclusion Criteria: * Renal artery stenosis * Symptomatic heart failure or known ejection fraction \< 40% * Myocardial infarction or stroke within 6 months * Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers * Pregnant or lactating females * Cancer within the last 5 years

Locations (1)

Novartis Pharmaceuticals

East Hanover, New Jersey, United States

Outcomes

Primary Outcomes

Change from baseline in left ventricular mass index after 52 weeks

Secondary Outcomes

Change from baseline in left ventricular mass after 52 weeks

Change from baseline in diastolic function after 52 weeks

Change from baseline in aorta function assessed blood pressure measurements after 52 weeks

Change from baseline in markers of fibrosis and increased heart size after 52 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.